FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20049

STATEMENT	OF C	HANGES	IN BENE	FICIAL	OWNER	SHIP

OMB APPRO	DVAL
OMB Number:	3235-0287
Estimated average burd	len
hours per response:	0.5
	OMB Number: Estimated average burd

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

									IIIVCStilicii		.,,							
1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [RARE]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
NARACHI MICHAEL													X Dire	ctor		10% O	vner	
(Last) (First) (Middle) C/O ULTRAGENYX PHARMACEUTICAL INC.						3. Date of Earliest Transaction (Month/Day/Year) 06/09/2016								Offic belo	er (give title w)		Other (sbelow)	specify
			UTICAL	IIVC.														
60 LEVE	ERONI CO	URI			4. 11	f Ame	ndment,	Date	of Original	Filed	(Month/D	ay/Year)	6.	Individual	or Joint/Grou	p Filin	g (Check Ap	plicable
(Ctt)					-								Lir	,		_		
(Street) NOVAT) C	A !	94949											For	n filed by Or n filed by Mo		•	
(City)	(Si	tate)	(Zip)											Per	son			
		Tab	le I - No	n-Deriv	/ative	Sec	curities	s Ac	quired,	Dis	oosed o	of, or Be	neficia	lly Own	ed			
1. Title of S	Security (Inst	tr. 3)		2. Trans	action	2	A. Deem	ed	3.		4. Securi	ties Acquii	ed (A) or	5. Am	ount of	6. Ov	vnership	7. Nature
Date (Month/D.				Day/Ye	ay/Year) Execution Date, if any (Month/Day/Year			r, Transaction Dispos Code (Instr. 5)		Dispose	ed Of (D) (Instr. 3, 4		Bene Owne	icially d Following	(D) o	rm: Direct) or Indirect (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) or (D) Pt			nsaction(s) str. 3 and 4)				
Common Stock 06/09/				9/2016	2016		A		1,875	1,875 ⁽¹⁾ A S		0	1,875		D			
		T	able II -						uired, D , option					y Owne	t			
			1			Calls		_		_				т				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date Exe (Month/Day/Year) if ar	Execution if any	Execution Date, f any		4. Transaction Code (Instr. B)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amount or Number of Shares					
Employee Stock Option (Right to	\$65.85	06/09/2016			A		3,750		(2)	0	5/09/2026	Common Stock	3,750	\$0.00	3,75	0	D	

Explanation of Responses:

- 1. Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 9, 2017.
- 2. The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 9, 2017.

Remarks:

/s/ Shalini Sharp by power of attorney for Michael Narachi

06/14/2016

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.